Download our Knowledge-base material
Download copies of our Knowledge-base material
Search results
Download copies of our Knowledge-base material
Our young adults got to grips with white water rafting recently, building confidence and resilience while having fun.
Early 2020 marked an important milestone for the Retina UK community, when the first person with an inherited retinal condition received NHS treatment to potentially slow or even stop the progression of their sight loss.
The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.
X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.
Researchers have developed PEDF-based eye drops that show promise in slowing retinal degeneration in mice with retinitis pigmentosa, potentially offering a non-invasive treatment option for preserving vision in the future.
Aavantgarde Bio Ush1B study at Moorfields
Octant, a clinical stage drug discovery company, has recently announced the dosing of the first healthy volunteer in their Phase 1a clinical trial of OCT-980 for Rhodopsin-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP).
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.